# EDGAR Filing Document

**Accession Number:** 0001913577
**File Stem:** 0001193125-25-330493
**Filing Date:** 2025-12
**Character Count:** 2787
**Document Hash:** ea06dcf09daf2c837349eeae403af313
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-330493.hdr.sgml**: 20260701

**ACCESSION NUMBER**: 0001193125-25-330493

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Semnur Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001913577
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981659463
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 960 SAN ANTONIO ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94303
- **BUSINESS PHONE:** (650) 516-4310

**MAIL ADDRESS:**
- **STREET 1:** 960 SAN ANTONIO ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94303

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Denali Capital Acquisition Corp.
- **DATE OF NAME CHANGE:** 20220224

Semnur Pharmaceuticals, Inc.

960 San Antonio Road

Palo Alto, CA 94303

December 23, 2025

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

Attention: Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549-0406

---

| | |
|:---|:---|
| **Re:** | **Semnur Pharmaceuticals, Inc.**  |

---

**Registration Statement on Form S-1, as amended** 

**File No. 333-290995** 

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Semnur Pharmaceuticals, Inc. (the "***Company***") hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-290995) of the Company, initially filed with the Securities and Exchange Commission on October 21, 2025 (as amended, the "***Registration Statement***"), be accelerated so that such Registration Statement shall become effective at 4:00 p.m., Eastern Time, on December 29, 2025, or as soon as possible thereafter.

It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com, and Elizabeth A. Razzano of Paul Hastings LLP, by telephone at (650) 320-1895 or by email at elizabethrazzano@paulhastings.com. The Company hereby authorizes Mr. Hartlin or Ms. Razzano of Paul Hastings LLP to orally modify or withdraw this request for acceleration.

---

| | |
|:---|:---|
|  Sincerely, | Sincerely, |
|  Semnur Pharmaceuticals, Inc. | Semnur Pharmaceuticals, Inc. |
|  By: | /s/ Jaisim Shah |
|  | Jaisim Shah |
|  | Chief Executive Officer and President |

---

cc: Jeffrey T. Hartlin, Paul Hastings LLP

Elizabeth A. Razzano, Paul Hastings LLP